Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 5,507 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo once daily Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Use of Modafinil in the Treatment of Tinnitus

NCT00591019
View directory record Official record
Conditions
Tinnitus
Interventions
Modafinil, Placebo
Drug · Other
Lead sponsor
University of Arkansas
Other
Eligibility
20 Years to 99 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 28, 2026, 9:58 PM EDT
Completed Phase 3 Interventional Results available

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

NCT01617434
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
31
States / cities
Phoenix, Arizona • Anaheim, California • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 28, 2026, 9:58 PM EDT
Completed Phase 2 Interventional Results available

Mitigation of Radiation Pneumonitis and Fibrosis

NCT01754909
View directory record Official record
Conditions
Lung Cancer, Radiation Pneumonitis
Interventions
Enalapril, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
35 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 28, 2026, 9:58 PM EDT
Completed Phase 3 Interventional Results available

Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)

NCT01964352
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, placebo, olodaterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
20
States / cities
Wheat Ridge, Colorado • Clearwater, Florida • Panama City, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 28, 2026, 9:58 PM EDT
Completed Phase 3 Interventional Results available

Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis

NCT00343252
View directory record Official record
Conditions
Osteoporosis, Postmenopausal, Back Pain, Spinal Fracture
Interventions
teriparatide, risedronate, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Female only
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • Montgomery, Alabama • Peoria, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated May 26, 2011 · Synced Oct 28, 2026, 9:58 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients

NCT04535609
View directory record Official record
Conditions
Primary Mitochondrial Myopathy
Interventions
Mavodelpar, Placebo
Drug
Lead sponsor
Reneo Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
La Jolla, California • Gainesville, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 28, 2026, 9:58 PM EDT
Completed Not applicable Interventional

Physiological Effects of Yogurt With Bb12 in Subjects With GI Symptoms Strointestinal Symptoms

NCT01004484
View directory record Official record
Conditions
Non-diarrhea Functional Bowel Symptoms
Interventions
A probiotic yogurt with inulin, Acidified dairy snack
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 21, 2010 · Synced Oct 28, 2026, 9:58 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)

NCT05660538
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Suzetrigine, Pregabalin, Placebo (matched to SUZ), Placebo (matched to pregabalin)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
50
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 28, 2026, 9:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of IVX-A12 in Healthy Older Adults

NCT05664334
View directory record Official record
Conditions
Healthy
Interventions
IVX-121, IVX-241, Placebo, MF59®
Biological · Other
Lead sponsor
Icosavax, Inc.
Industry
Eligibility
60 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Hollywood, Florida • Atlanta, Georgia • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 28, 2026, 9:58 PM EDT
Terminated Phase 3 Interventional

Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia

NCT00249899
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Lapaquistat acetate and stable statin therapy, Stable statin therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
13
States / cities
Santa Ana, California • Chicago, Illinois • Iowa City, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Oct 28, 2026, 9:58 PM EDT
Completed Phase 3 Interventional Results available

Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

NCT01165138
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate/Vilanterol Inhalation Powder, Fluticasone Furoate Inhalation Powder, Placebo Inhaltion Powder
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Bell Gardens, California • Huntington Beach, California • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 28, 2026, 9:58 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma

NCT00843193
View directory record Official record
Conditions
Asthma
Interventions
INTRAVENOUS GSK679586, INTRAVENOUS PLACEBO, FLUTICASONE PROPIONATE
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Medford, Oregon • Portland, Oregon • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 28, 2026, 9:58 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Clonidine Lauriad® to Treat Oral Mucositis

NCT01385748
View directory record Official record
Conditions
Oral Mucositis
Interventions
Clonidine Lauriad® 50µg, Clonidine Lauriad® 100µg, Placebo Lauriad®
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
19
States / cities
Sun City, Arizona • Corona, California • Duarte, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 28, 2026, 9:58 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension

NCT06168409
View directory record Official record
Conditions
Resistant Hypertension
Interventions
Baxdrostat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
16
States / cities
Surprise, Arizona • Hollywood, Florida • Lake Worth, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 28, 2026, 9:58 PM EDT
Completed Not applicable Interventional Results available

Predicting Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients

NCT01377987
View directory record Official record
Conditions
Heart Failures
Interventions
Acetazolamide, Placebo
Drug
Lead sponsor
David Andrew Wellman
Other
Eligibility
18 Years to 89 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 28, 2026, 9:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease

NCT03998514
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
CB4211 Dose 1, CB4211 Dose 2, CB4211 Dose 3, CB4211 Dose 4, CB4211 Dose 5, CB4211 Dose 6, CB4211 Dose TBD, Placebo
Drug
Lead sponsor
CohBar, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
4
States / cities
Chula Vista, California • Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 28, 2026, 9:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of TCMCB07 in Single and Multiple Ascending Doses in Health Subjects

NCT05529849
View directory record Official record
Conditions
Cachexia
Interventions
TCMCB07, Placebo
Drug
Lead sponsor
Endevica Bio
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 28, 2026, 9:58 PM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

NCT05834738
View directory record Official record
Conditions
IgA Nephropathy, Immunoglobulin A Nephropathy
Interventions
Atrasentan, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • Atlanta, Georgia • Oak Brook, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 28, 2026, 9:58 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients

NCT00418886
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Lung Cancer
Interventions
Vandetanib, Pemetrexed
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
23
States / cities
Casa Grande, Arizona • Chandler, Arizona • Farmington, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Oct 28, 2026, 9:58 PM EDT
Terminated Phase 2 Interventional

Cholecalciferol Supplementation in Strengthening Inspiratory Muscles in Cholecalciferol-Deficient Patients With Chronic Obstructive Pulmonary Disease

NCT02877641
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Muscle Weakness
Interventions
Cholecalciferol, Laboratory Biomarker Analysis, Multivitamin, Placebo, Questionnaire Administration
Dietary Supplement · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
50 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 28, 2026, 9:58 PM EDT
Completed Phase 3 Interventional

Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Soft Tissue Injuries (TAPED)

NCT00931866
View directory record Official record
Conditions
Acute Pain, Soft Tissue Injury
Interventions
Diclofenac Sodium, Matching Placebo Patch
Drug
Lead sponsor
Cerimon Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Oct 28, 2026, 9:58 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

NCT02471222
View directory record Official record
Conditions
Walking Impairment, Multiple Sclerosis
Interventions
ADS-5102, Placebo
Drug · Other
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Phoenix, Arizona • Aurora, Colorado • Sarasota, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 28, 2026, 9:58 PM EDT
Completed Phase 3 Interventional

A Comparison Of Valdecoxib 20 Mg Twice Daily and 40 Mg Daily and Placebo In The Treatment Of Sore Throat

NCT00647829
View directory record Official record
Conditions
Pharyngitis
Interventions
valdecoxib, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
2
States / cities
Storrs, Connecticut • Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Apr 24, 2008 · Synced Oct 28, 2026, 9:58 PM EDT
Terminated Phase 2 Interventional

DNS-7801 vs. Placebo in Parkinson's Disease

NCT03306329
View directory record Official record
Conditions
Parkinson's Disease
Interventions
DNS-7801 (low-dose), DNS-7801 (high dose), Placebo
Drug
Lead sponsor
Dart NeuroScience, LLC
Industry
Eligibility
30 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
9
States / cities
Long Beach, California • Pasadena, California • Englewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Oct 28, 2026, 9:58 PM EDT